Ichor (ICHR) Q1 2026 Earnings Call Transcript

Ichor Holdings posted Q1 revenue of $256.1 million, up 15% sequentially, with gross margin expanding 110 bps to 12.8% and operating income more than tripling to $8.7 million. Management guided Q2 revenue to $290 million-$310 million, gross margin to 13%-14%, and EPS to $0.25-$0.35, while reiterating expectations for roughly 100 bps of gross margin expansion per quarter through year-end. The call also highlighted strong demand visibility, capacity expansion in Mexico and Malaysia, and improving mix from higher internal sourcing and branded content.

Analysis

ICHR is shifting from a cyclical supplier to a capacity-constrained operating lever on advanced-node capex. The important second-order effect is that the company is not just riding WFE demand; it is gaining share in the part of the bill of materials where vertical content and internal sourcing can compound margins as volumes rise. That makes the next 2-3 quarters less about top-line sensitivity and more about how quickly Mexico/Malaysia qualification converts external spend into proprietary mix.

The market may underappreciate how much of the near-term upside is self-help rather than pure demand beta. If the company truly sustains 100 bps gross margin expansion per quarter, operating leverage will accelerate faster than consensus models that assume linear margin improvement, especially as branded content displaces outsourced components. The implication is that earnings revisions should outpace revenue revisions into Q3/Q4, which tends to drive multiple expansion in semicap suppliers with improving visibility.

The main risk is not demand collapsing; it is execution friction at exactly the point where growth is strongest. Inventory builds, headcount ramp, supplier bottlenecks, and equipment timing create a narrow window where any misstep could temporarily compress cash conversion and stall margin progression. The contrarian angle is that the stock can become crowded on “2027 growth optionality,” but if the market starts capitalizing only the current run-rate and not the capacity expansion story, upside still exists over a 6-12 month horizon.

Key Decisions for Investors

• Add to ICHR on any post-earnings pullback over the next 5-10 trading days; target a 6-9 month hold for margin-revision upside. Risk/reward is attractive if the market has not fully priced the Q3/Q4 gross margin inflection.
• Use a call spread in ICHR (3-6 month tenor) to express upside to the 2026 earnings reset with defined downside. The trade works if the market re-rates the name on higher forward EPS rather than waiting for actual margin delivery.
• Pair long ICHR vs short a lower-quality WFE supplier with less vertical content and weaker self-help, over a 3-6 month horizon. The relative value thesis is that ICHR’s revisions should accelerate faster than peers as internal sourcing ramps.
• If already long semicap beta, rotate incremental exposure from pure-cycle names into ICHR. The better risk/reward is in businesses with visible operational transformation, not just exposure to AI capex.
• Set a trailing stop around any failure to convert Q2/Q3 revenue growth into expanding gross margin; if margin guidance stops moving up, the thesis loses its catalyst and the multiple can de-rate quickly.